Myelodysplasia

[1]  P. N. Rao,et al.  Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. , 1999, Blood.

[2]  S. Scherer,et al.  Delineation of multiple deleted regions in 7q in myeloid disorders , 1999, Genes, chromosomes & cancer.

[3]  R. Larson,et al.  Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. , 1999, Blood.

[4]  B. Hirshberg,et al.  6;9 translocation in myelodysplastic syndrome. , 1999, Cancer genetics and cytogenetics.

[5]  T. Economopoulos,et al.  Treatment of anemia in low risk myelodysplastic syndromes with granulocyte–macrophage colony-stimulating factor plus recombinant human erythropoietin , 1999, Leukemia.

[6]  J. Anastasi,et al.  Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation , 1999, Bone Marrow Transplantation.

[7]  J. Miguel,et al.  Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS , 1999, Bone Marrow Transplantation.

[8]  G. Sanchez-Williams,et al.  Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells , 1999, Leukemia.

[9]  J. Tooze,et al.  Clonal evolution of aplastic anaemia to myelodysplasia/acute myeloid leukaemia and paroxysmal nocturnal haemoglobinuria. , 1999, Leukemia & lymphoma.

[10]  A. Hagemeijer,et al.  Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2‐chloro‐2′‐deoxyadenosine , 1999, British journal of haematology.

[11]  J. Downing,et al.  Cloning and chromosomal localization of the gene encoding human cyclin D-binding Myb-like protein (hDMP1). , 1999, Gene.

[12]  H. Handa,et al.  Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. , 1999, Leukemia research.

[13]  B. Freidlin,et al.  Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  B. Johansson,et al.  A single‐center population‐based consecutive series of 1500 cytogenetically investigated adult hematological malignancies: karyotypic features in relation to morphology, age and gender , 1999, European journal of haematology.

[15]  Z. Zemanová,et al.  Double minute chromosomes in a patient with myelodysplastic syndrome transforming into acute myeloid leukemia. , 1999, Cancer genetics and cytogenetics.

[16]  C. Willman.  Molecular genetic features of myelodysplastic syndromes (MDS) , 1999, Leukemia.

[17]  Hepburn,et al.  Poor response rate to a continuous schedule of Amifostine therapy for ‘low/intermediate risk’ myelodysplastic patients , 1998, British journal of haematology.

[18]  M. Andersen,et al.  Cytogenetically unrelated clones in therapy‐related myelodysplasia and acute myeloid leukemia: Experience from the Copenhagen series updated to 180 consecutive cases , 1998, Genes, chromosomes & cancer.

[19]  S. Scherer,et al.  Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. , 1998, Blood.

[20]  P. Greenberg,et al.  Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. , 1998, Leukemia research.

[21]  M. Elghetany,et al.  Significance of p53 overexpression in bone marrow biopsies from patients with bone marrow failure: aplastic anemia, hypocellular refractory anemia, and hypercellular refractory anemia , 1998, Annals of Hematology.

[22]  Parker,et al.  ‘Low‐risk’ myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro‐ versus anti‐apoptotic bcl‐2‐related proteins , 1998, British journal of haematology.

[23]  N. Takahashi,et al.  Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes. , 1998, Blood.

[24]  N. Kamada,et al.  19-nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. , 1998, Blood.

[25]  C. Felix.  Secondary leukemias induced by topoisomerase-targeted drugs. , 1998, Biochimica et biophysica acta.

[26]  C. de Angeli,et al.  Exposure to myelotoxic agents and myelodysplasia: case–control study and correlation with clinicobiological findings , 1998, British journal of haematology.

[27]  F. Appelbaum,et al.  Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. , 1998, Leukemia.

[28]  A. Barrett,et al.  Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte‐mediated inhibition of CFU‐GM and alterations in T‐cell receptor Vβ profiles , 1998, British journal of haematology.

[29]  T. Katagiri,et al.  Vitamin K2 selectively induces apoptosis of blastic cells in myelodysplastic syndrome: flow cytometric detection of apoptotic cells using APO2.7 monoclonal antibody , 1998, Leukemia.

[30]  R. Davis,et al.  Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. , 1998, Leukemia research.

[31]  M. Lazzarino,et al.  Randomized clinical study comparing aggressive chemotherapy with or without G‐CSF support for high‐risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS , 1998, British journal of haematology.

[32]  G. Verhoef,et al.  Patients with high‐risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission , 1998, British journal of haematology.

[33]  I. Dybedal,et al.  Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. , 1998, Blood.

[34]  S. Horiike,et al.  Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer. , 1998, International journal of oncology.

[35]  A. Gratwohl,et al.  Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey , 1998, Bone Marrow Transplantation.

[36]  S. Chevret,et al.  RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up , 1998, Leukemia.

[37]  B. Cheson,et al.  Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. , 1998, Leukemia research.

[38]  G. Flandrin,et al.  FISH investigation of 5q and 7q deletions in MDS/AML reveals hidden translocations, insertions and fragmentations of the same chromosomes. , 1998, Leukemia research.

[39]  K. Hirokawa,et al.  Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia , 1998, Leukemia.

[40]  J. Sosman,et al.  A phase II trial of interleukin‐2 in myelodysplastic syndromes , 1998, British journal of haematology.

[41]  Bolam,et al.  Association of myelodysplastic changes with purine analogues , 1998, British journal of haematology.

[42]  W. Ludwig,et al.  Correlation of cytogenetic, molecular cytogenetic, and clinical findings in 59 patients with ANLL or MDS and abnormalities of the short arm of chromosome 12 , 1998, British journal of haematology.

[43]  N. Young,et al.  Antithymocyte globulin for patients with myelodysplastic syndrome , 1997, British journal of haematology.

[44]  E. Wattel,et al.  Long‐term follow‐up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long‐term survivors and outcome of partial responders , 1997, British journal of haematology.

[45]  W. Du,et al.  Successful allogeneic bone marrow transplantation in selected patients over 50 years of age – a single institution’s experience , 1997, Bone Marrow Transplantation.

[46]  A. Crescenzi,et al.  Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[48]  P. Koistinen,et al.  Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. , 1997, Leukemia research.

[49]  P. Greenberg,et al.  Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. , 1996, Blood.

[50]  H. van den Berghe,et al.  Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. , 1996, Bone marrow transplantation.

[51]  K. Sullivan,et al.  Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS‐related acute myeloid leukaemia , 1996, British journal of haematology.

[52]  H. Zwierzina,et al.  Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). , 1995, Leukemia.

[53]  C. Preudhomme,et al.  Combined immunophenotyping and in situ hybridization (FICTION): a rapid method to study cell lineage involvement in myelodysplastic syndromes , 1995, British journal of haematology.

[54]  L. Lessin,et al.  The use of r‐HuEpo in the treatment of anaemia related to myelodysplasia (MDS) , 1995, British journal of haematology.

[55]  E. Hellström-Lindberg.  Efficacy of erythropoietin in the myelodysplastic syndromes: a meta‐analysis of 205 patients from 17 studies , 1995, British journal of haematology.

[56]  J. Uberti,et al.  Allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. , 1994, Leukemia & lymphoma.

[57]  Y. Kagami,et al.  Recovery of polyclonal hematopoiesis in patients with myelodysplastic syndromes following successful chemotherapy. , 1994, Leukemia.

[58]  C. Bloomfield,et al.  Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. , 1992, Seminars in oncology.

[59]  R. Abels,et al.  Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. , 1991, Blood.

[60]  C. Haanen,et al.  Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia , 1990, Cancer.

[61]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[62]  W. Hiddemann,et al.  Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes , 1999, Journal of Cancer Research and Clinical Oncology.

[63]  I. Bernstein,et al.  Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. , 1999, Blood.

[64]  A. Miller,et al.  Limited erythropoietic response to combined treatment with recombinant human interleukin 3 and erythropoietin in myelodysplastic syndrome. , 1999, Leukemia research.

[65]  M. Yaguchi,et al.  Vitamin K2 therapy for a patient with myelodysplastic syndrome , 1999, Leukemia.

[66]  H. Mizoguchi,et al.  Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome. , 1999, Leukemia research.

[67]  R. Kratzke,et al.  Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival , 1999, Leukemia.

[68]  H. Kantarjian,et al.  Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy , 1999, Leukemia.

[69]  B. Johansson,et al.  Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements. , 1998, Haematologica.

[70]  M. Cazzola,et al.  A patient-oriented approach to treatment of myelodysplastic syndromes. , 1998, Haematologica.

[71]  E. Estey,et al.  Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. , 1998, Leukemia & lymphoma.

[72]  P. Néve,et al.  Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome , 1997, Leukemia.

[73]  M. Labopin,et al.  Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. , 1997, Blood.

[74]  T. Economopoulos,et al.  Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor. (GM-CSF). , 1996, Leukemia research.

[75]  F. V. van Leeuwen.  Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. , 1996, Bailliere's clinical haematology.

[76]  P. Kluin,et al.  Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes. , 1992, Blood.